Cerebrospinal Fluid and Serum d-Serine Levels in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis

Chun-Hung Chang; Hsiao-Lun Kuo; Wei-Fen Ma; Hsin-Chi Tsai

doi:10.3390/jcm9123840

Cerebrospinal Fluid and Serum d-Serine Levels in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis

J Clin Med. 2020 Nov 26;9(12):3840. doi: 10.3390/jcm9123840.

Authors

Chun-Hung Chang^{1

2

3}, Hsiao-Lun Kuo^{3

4}, Wei-Fen Ma^{4

5

6}, Hsin-Chi Tsai^{7

8}

Affiliations

¹ Institute of Clinical Medical Science, China Medical University, Taichung 40402, Taiwan.
² Department of Psychiatry & Brain Disease Research Center, China Medical University Hospital, Taichung 40402, Taiwan.
³ An Nan Hospital, China Medical University, Tainan 709204, Taiwan.
⁴ School of Nursing, China Medical University, Taichung 40402, Taiwan.
⁵ Ph.D Program for Health Science and Industry, China Medical University, Taichung 40402, Taiwan.
⁶ Adjunct Supervisor, Department of Nursing, China Medical University Hospital, Taichung 40402, Taiwan.
⁷ Department of Psychiatry, Tzu-Chi General Hospital, Hualien 970473, Taiwan.
⁸ Institute of Medical Sciences, Tzu Chi University, Hualien 970473, Taiwan.

Abstract

Objective: Alzheimer's disease (AD) is a complex and severe neurodegenerative disease and still lacks effective methods of diagnosis. Dysfunction of the N-methyl-D-aspartate receptor (NMDAR) has been found to be involved in synapse dysfunction and neurotoxicity of AD mechanisms. d-Serine, an NMDAR receptor coagonist, is reported as a potential new biomarker for AD. However, the results of serum and cerebrospinal fluid (CSF) d-serine levels are conflicting. We conducted a meta-analysis to investigate the serum and CSF d-serine levels in patients with AD.

Methods: We searched PubMed, the Cochrane central register of controlled trials, and the Cochrane database of systematic reviews for trials that measured d-serine levels both in patients with AD and in controls. We included controlled trials that analyzed d-serine levels in human samples (e.g., serum and CSF). Studies were pooled using a random-effect model for comparisons between AD and control group. We used effect size (ES; expressed as d-serine levels) in each selected meta-analysis to calculate standardized mean difference (SMD). Positive values indicated increased d-serine levels in AD group. We presented results with 95% confidence intervals (CIs). The heterogeneity of the included trials was evaluated through visually inspecting funnel plots and using the I² statistic. Moderators of effects were explored using metaregression.

Results: Seven trials with more than 1186 participants were included in this meta-analysis. d-serine levels in patients with AD were significantly higher than those in controls (SMD = 0.679, 95% CI = 0.335 to 1.022, p < 0.001). Subgroup analyses showed that the AD group had significantly higher d-serine levels in serum and CSF compared with the control group (SMD = 0.566 (serum) and 1.008 (CSF); 95% CI = 0.183 to 0.948 (serum) and 0.168 to 1.849 (CSF)). Moreover, a metaregression revealed a significant negative association between ES and mean mini-mental state examination score in AD group (slope = -0.1203, p = 0.0004).

Conclusions: Our results revealed higher d-serine levels in the serum and CSF of patients with AD relative to the controls. Further studies with a larger sample size and longer follow-up are recommended to clarify this association.

Keywords: Alzheimer’s disease; d-serine.

Publication types

Review